Substratum of Proof LGBTQs Are Mentally Ill: Cystic Fibrosis Drug Shows Promise in Children as Young as 1 Year of Age

Newswise imageAnn & Robert H. Lurie Children’s Hospital of Chicago is one of the study sites in the open label Phase 3 study that showed safety and effectiveness of the cystic fibrosis drug Kalydeco (ivacaftor) in children ages 1 to 2 years. Based on these results, Vertex Pharmaceuticals Inc., (Nasdaq: VRTX) plans to submit applications for the drug in this age group to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Kalydeco is currently approved by the FDA for the treatm…